-
Something wrong with this record ?
The inhibitory effect of antiretroviral drugs on the L-carnitine uptake in human placenta
R. Karahoda, M. Ceckova, F. Staud,
Language English Country United States
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Anti-Retroviral Agents toxicity MeSH
- Biological Transport MeSH
- Risk Assessment MeSH
- Carnitine metabolism MeSH
- Humans MeSH
- Maternal Exposure adverse effects MeSH
- Cell Line, Tumor MeSH
- Placenta drug effects metabolism MeSH
- Organic Cation Transport Proteins antagonists & inhibitors metabolism MeSH
- Solute Carrier Family 22 Member 5 antagonists & inhibitors metabolism MeSH
- Pregnancy MeSH
- Check Tag
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
In spite of remarkable reduction in the number of children born with HIV due to antiretroviral therapy, concerns remain on the short- and long-term effects of antiretroviral drugs at the feto-placental unit. Cardio- and skeletal myopathies have been reported in children exposed to antiretroviral drugs prenatally. These conditions have also been described in perturbed placental transfer of l-carnitine, an essential co-factor in fatty acid oxidation. Due to limited fetal and placental synthesis, carnitine supply is maintained through the placental carnitine uptake from maternal blood by the organic cation/carnitine transporters OCTN1 and OCTN2 (SLC22A4 and SLC22A5, respectively). The aim of our study was to investigate potential inhibition of placental carnitine uptake by a broad range of antiretroviral drugs comprising nucleoside/nucleotide reverse transcriptase inhibitors (lamivudine, zidovudine, abacavir, tenofovir disoproxil fumarate), non-nucleoside reverse transcriptase inhibitors (rilpivirine, efavirenz, etravirine), protease inhibitors (ritonavir, lopinavir, atazanavir, saquinavir, tipranavir), integrase inhibitors (raltegravir, dolutegravir, elvitegravir) and viral entry inhibitor, maraviroc. Studies in choriocarcinoma BeWo cells and human placenta-derived models confirmed predominant expression and function of OCTN2 above OCTN1 in l-carnitine transport. Subsequent screenings in BeWo cells and isolated MVM vesicles revealed seven antiretroviral drugs as inhibitors of the Na+-dependent l-carnitine uptake, corresponding to OCTN2. Ritonavir, saquinavir and elvitegravir showed the highest inhibitory potential which was further confirmed for ritonavir and saquinavir in placental fresh villous fragments. Our data indicate possible impairment in placental and fetal supply of l-carnitine with ritonavir and saquinavir, while suggesting retained placental carnitine transport with the other antiretroviral drugs.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045006
- 003
- CZ-PrNML
- 005
- 20200120102804.0
- 007
- ta
- 008
- 200109s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.taap.2019.02.002 $2 doi
- 035 __
- $a (PubMed)30735677
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Karahoda, Rona $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Czech Republic.
- 245 14
- $a The inhibitory effect of antiretroviral drugs on the L-carnitine uptake in human placenta / $c R. Karahoda, M. Ceckova, F. Staud,
- 520 9_
- $a In spite of remarkable reduction in the number of children born with HIV due to antiretroviral therapy, concerns remain on the short- and long-term effects of antiretroviral drugs at the feto-placental unit. Cardio- and skeletal myopathies have been reported in children exposed to antiretroviral drugs prenatally. These conditions have also been described in perturbed placental transfer of l-carnitine, an essential co-factor in fatty acid oxidation. Due to limited fetal and placental synthesis, carnitine supply is maintained through the placental carnitine uptake from maternal blood by the organic cation/carnitine transporters OCTN1 and OCTN2 (SLC22A4 and SLC22A5, respectively). The aim of our study was to investigate potential inhibition of placental carnitine uptake by a broad range of antiretroviral drugs comprising nucleoside/nucleotide reverse transcriptase inhibitors (lamivudine, zidovudine, abacavir, tenofovir disoproxil fumarate), non-nucleoside reverse transcriptase inhibitors (rilpivirine, efavirenz, etravirine), protease inhibitors (ritonavir, lopinavir, atazanavir, saquinavir, tipranavir), integrase inhibitors (raltegravir, dolutegravir, elvitegravir) and viral entry inhibitor, maraviroc. Studies in choriocarcinoma BeWo cells and human placenta-derived models confirmed predominant expression and function of OCTN2 above OCTN1 in l-carnitine transport. Subsequent screenings in BeWo cells and isolated MVM vesicles revealed seven antiretroviral drugs as inhibitors of the Na+-dependent l-carnitine uptake, corresponding to OCTN2. Ritonavir, saquinavir and elvitegravir showed the highest inhibitory potential which was further confirmed for ritonavir and saquinavir in placental fresh villous fragments. Our data indicate possible impairment in placental and fetal supply of l-carnitine with ritonavir and saquinavir, while suggesting retained placental carnitine transport with the other antiretroviral drugs.
- 650 _2
- $a antiretrovirové látky $x toxicita $7 D044966
- 650 _2
- $a biologický transport $7 D001692
- 650 _2
- $a karnitin $x metabolismus $7 D002331
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a matka - expozice noxám $x škodlivé účinky $7 D018811
- 650 _2
- $a proteiny přenášející organické kationty $x antagonisté a inhibitory $x metabolismus $7 D027701
- 650 _2
- $a placenta $x účinky léků $x metabolismus $7 D010920
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rodina nosičů rozpuštěných látek 22, člen 5 $x antagonisté a inhibitory $x metabolismus $7 D000074058
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ceckova, Martina $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Czech Republic. Electronic address: martina.ceckova@faf.cuni.cz.
- 700 1_
- $a Staud, Frantisek $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Czech Republic.
- 773 0_
- $w MED00010691 $t Toxicology and applied pharmacology $x 1096-0333 $g Roč. 368, č. - (2019), s. 18-25
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30735677 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200120103140 $b ABA008
- 999 __
- $a ok $b bmc $g 1483275 $s 1083679
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 368 $c - $d 18-25 $e 20190205 $i 1096-0333 $m Toxicology and applied pharmacology $n Toxicol Appl Pharmacol $x MED00010691
- LZP __
- $a Pubmed-20200109